Jai Parekh, MD
Ophthalmology · Woodland Park, NJNPI 1841222502
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), consulting fees and ownership interests — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Sight Sciences, Inc. at 24.8% of the total. 2025 is the largest year on record at $447,595, more than ten times the $1,327 reported in 2019. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,262 payments — averaging $862.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$485K
- Bausch & Lomb Americas Inc.$310K
- Ocular Therapeutix, Inc.$261K
- Tarsus Pharmaceuticals, Inc.$224K
- AbbVie$221K
- Sun Pharmaceutical Industries Inc.$150K
- plus $302K from 34 others
Across 10 payments — averaging $7708.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$61K
- Bausch & Lomb Americas Inc.$16K
Across 9 payments — averaging $3324.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Alafair Biosciences, Inc.$30K
- Paragon 28, Inc.$0
- Nextremity Solutions Inc.$0
- Rapid Pathogen Screening, Inc.$0
What the payments were for
- Consulting fees$671,18434%
- Speaking & faculty fees$869,58445%
- Travel & lodging$100,8845%
- Food & beverage$64,4113%
- Education$1690%
- Gifts$450%
- Ownership interest$245,50813%
- Other$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$205,984
- MIEBO$189,765
- TearCare SmartLid$188,505
- TEARCARE(TM) (2.2) SYSTEM KIT$188,505
- OMNI(R) SURGICAL SYSTEM (US)$182,828
- XIIDRA$160,300
- CEQUA$146,927
- DURYSTA$118,323
- VUITY$86,102
- TEARCARE SYSTEM$76,543
- enVista MX60 IOL$50,444
- TYRVAYA$46,877
- SION SURGICAL INSTRUMENT$45,644
- Travoprost Intraocular Implant - iDose$42,045
- Kahook Dual Blade$31,352
- Ahmed Glaucoma Valve$31,352
- TearCare$30,476
- Clearpath$29,942
- Streamline$29,942
- Oxervate$28,718
How this compares
$1,951,924 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,240 | $1,333,868 |
| XiidraLifitegrast | 963 | $1,152,426 |
| Cyclosporine | 968 | $572,624 |
| OxervateCenegermin-Bkbj | 13 | $531,069 |
| LumiganBimatoprost | 1,201 | $518,457 |
| CequaCyclosporine | 287 | $250,959 |
| MieboPerfluorohexyloctane/Pf | 142 | $127,997 |
| CombiganBrimonidine Tartrate/Timolol | 374 | $119,104 |
| VyzultaLatanoprostene Bunod | 199 | $94,252 |
| XdemvyLotilaner | 44 | $82,078 |
| RhopressaNetarsudil Mesylate | 174 | $79,452 |
| RocklatanNetarsudil Mesylat/Latanoprost | 127 | $52,578 |
| TyrvayaVarenicline Tartrate | 52 | $48,783 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 151 | $43,997 |
| VevyeCyclosporine | 56 | $43,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $220,770 | $2,013,9512,897 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $310,416 | $1,374,6741,304 claims |
| Dompe US, Inc.Oxervate | $29,800 | $531,06913 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $149,932 | $250,959287 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $359 | $132,031301 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $223,859 | $82,07844 claims |
| AlconSimbrinza, Azopt | $1,498 | $53,471166 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $48,305 | $48,78352 claims |
| Harrow Eye, LLCVevye | $862 | $43,31656 claims |
| Eyevance Pharmaceuticals LLCZerviate | $2,135 | $34,692115 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Zylet, Lotemax, Lotemax Sm | $23,931 | $29,11888 claims |
| NovartisIlevro | $10,178 | $28,59979 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Woodland Park
- Swati ParekhWoodland Park$41K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.